Compare Enveric Biosciences Inc (ENVB) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs RLX Technology Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while RLX Technology Inc trades at $2.03 (market cap $2.46B). The key difference: RLX Technology Inc is far larger — about 462.4× Enveric Biosciences Inc's market cap, and RLX Technology Inc pays a 4.98% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | RLX | |
|---|---|---|
Market Cap | $5.32M | $2.46B |
Sector | Health | Technology |
52-Week High | $17.40 | $2.73 |
52-Week Low | $1.28 | $1.79 |
Enterprise Value | $408.82K | $1.09B |
Dividend Yield | — | 4.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
RLX trades at $2.025, up 2.27% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. With a P/E of 18.37 and strong cash flow from operations of $1.10B in 2025, fundamentals show profitability but recent earnings underperformance warrants attention.
The outlook is mixed; RLX operates in a high-growth vaping market projected to reach $462bn by 2033, and it is debt-free with a cash-rich balance sheet. However, risks include regulatory pressures in China and consistent earnings misses. Analyst sentiment is neutral with a single hold rating, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
